National Institute on Drug Abuse (NIDA)

108 total trials 41 currently recruiting 67 completed

Trial Pipeline

RECRUITING Phase 1

Environment and Alcohol: A Pilot Study

NCT06860607

RECRUITING Early Phase 1

Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making

NCT06561828

RECRUITING

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

NCT06676059

RECRUITING

Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP

NCT06552741

RECRUITING Phase 3

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799

RECRUITING Phase 2

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT06015893

RECRUITING Phase 1

Spironolactone in Alcohol Use Disorder (SAUD)

NCT05807139

RECRUITING

Development and Validation of Learning and Decision-Making Tasks

NCT05707806

RECRUITING NA

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781

RECRUITING NA

Defining Neurobiological Links Between Substance Use and Mental Illness

NCT05538910

RECRUITING Phase 1

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

NCT05143424

RECRUITING

Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder

NCT03745339

RECRUITING NA

Mechanism of Non-invasive Magnetic Stimulation

NCT03394066

RECRUITING NA

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

NCT01036581

COMPLETED Phase 1

SXC-2023 Cocaine Interaction Study

NCT06343532

COMPLETED

Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study

NCT03152760

COMPLETED Phase 1

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599

COMPLETED

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

NCT02225184

COMPLETED NA

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614

COMPLETED Phase 2

Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

NCT01844687

COMPLETED

Individual Differences in Reward and Impulse Control

NCT01621607

COMPLETED

Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms

NCT01505725

COMPLETED

Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

NCT01031563

COMPLETED

Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality

NCT01031433

COMPLETED Phase 1

Vigabatrin Ph 1 Cocaine Interaction Study

NCT00626834

COMPLETED Phase 2

Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence

NCT00520286

COMPLETED

PET Imaging of Nicotinic Acetylcholine Receptors

NCT01046513

COMPLETED Phase 2

Evaluating Alternative Aftercare Models for Ex-offenders

NCT01586689

COMPLETED

Screening Protocol for the Evaluation of Potential Research Subjects

NCT01036971

COMPLETED Phase 1

Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers

NCT01034020

COMPLETED Phase 1

Emergency Department Initiated Tobacco Treatment (EDITT)

NCT00252902

COMPLETED

Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms

NCT01603992

COMPLETED

Dopamine Function and Reward Processing In Schizophrenia

NCT01035996

COMPLETED Phase 2

Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1

NCT00218517

COMPLETED Phase 2

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

NCT00129272

COMPLETED Phase 1

Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management

NCT00292110

COMPLETED NA

Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1

NCT00218556

COMPLETED NA

Positive Choice: Prevention for Positive Health

NCT00447707

COMPLETED Phase 4

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

NCT00015301

COMPLETED Phase 2

Bupropion for the Treatment of Methamphetamine Dependence - 1

NCT00069251

COMPLETED Phase 1

Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1

NCT00136825

COMPLETED Phase 2

Comparison of Buprenorphine and Methadone - 3

NCT00000334

COMPLETED Phase 1

Cocaethylene as a Treatment for Cocaine Dependence - 1

NCT00124696

COMPLETED Phase 2

Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use

NCT00218270

COMPLETED NA

Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals

NCT00870792

COMPLETED

Effects of Nicotine on Brain Activity as Measured by fMRI

NCT01037153

COMPLETED Phase 2

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

NCT00510016

COMPLETED Phase 4

Effects of Buspirone in Opiate Withdrawal

NCT00326235

COMPLETED Phase 2

Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens

NCT00218127

COMPLETED Phase 2

Evaluation of Benztropine for Cocaine Craving - 2

NCT00000333

COMPLETED Phase 2

Ondansetron for the Treatment of Cocaine Dependence - 1

NCT00033085

COMPLETED NA

Randomized Trial of the Positive Action Program in Hawaii Schools

NCT00328445

COMPLETED Phase 2

Reduction of Smoking in Cardiac Disease Patients

NCT00469885

COMPLETED

Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence

NCT01034384

COMPLETED Phase 3

Naltrexone Augmentation of Nicotine Patch Therapy - 1

NCT00218153

COMPLETED Phase 4

Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

NCT00015340

COMPLETED Phase 2

Progesterone Treatment in Female Smokers - 12

NCT00000295

COMPLETED Phase 1

Cocaine-Methylphendidate Interaction Study - 4

NCT00015067

COMPLETED Phase 2

Effects of Labetalol on Human Cocaine Use - 8

NCT00000291

COMPLETED Phase 2

Buprenorphine Detoxification - BBDVI - 19

NCT00000237

COMPLETED Phase 2

Tyrosine for Methamphetamine Dependence - 1

NCT00000322

COMPLETED Phase 4

Modeling Impaired Judgement in Cocaine Abusers - 6

NCT00015236

COMPLETED Phase 2

The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1

NCT00158288

COMPLETED Phase 1

Prepulse Inhibition of Startle in Cocaine Dependence - 7

NCT00015249

COMPLETED Phase 1

Buprenorphine and Naloxone Combination Study - 10

NCT00015288

COMPLETED Phase 2

Cocaine Abuse and ADHD - 10

NCT00000275

COMPLETED

Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

NCT00000323

COMPLETED Phase 2

Risperidone for the Treatment of Cocaine Dependence - 7

NCT00000342

COMPLETED Phase 2

Role of Metabolites in Nicotine Dependence (2) - 5

NCT00000288

COMPLETED NA

Cocaine Abuse and Attention Deficit Disorder - 3

NCT00000268

COMPLETED Phase 2

Role of Metabolites in Nicotine Dependence (1) - 1

NCT00000284

COMPLETED Phase 2

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

NCT00000318

COMPLETED Phase 2

Alternate-Day Buprenorphine Administration. Phase VII - 8

NCT00000226

COMPLETED Phase 2

Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1

NCT00000266

COMPLETED Phase 2

Flupenthixol Decanoate in Methamphetamine Smoking - 1

NCT00000241

COMPLETED Phase 2

Buprenorphine Maintenance for Opiate Dependence - 6

NCT00000357

COMPLETED Phase 2

Pharmacological Modulation of Cocaine Effects - 1

NCT00000201

COMPLETED Phase 2

Risperidone Treatment in Dually-Diagnosed Individuals - 2

NCT00000267

COMPLETED Phase 2

Buprenorphine Pharmacology Related to Addiction Treatment - 18

NCT00000236

COMPLETED Phase 1

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

NCT00000358

COMPLETED Phase 3

Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

NCT00000302

What the Pipeline for National Institute on Drug Abuse (NIDA) Shows

According to the ClinicalTrials.gov registry, National Institute on Drug Abuse (NIDA) is linked to 108 US clinical trials across every stage of research activity. Of those, 41 studies are currently recruiting — about 38% of the sponsor's indexed portfolio — and 67 are already marked complete, representing roughly 62% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for National Institute on Drug Abuse (NIDA) reports 34 late-stage studies (Phase 3 and Phase 4 combined) and 47 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for National Institute on Drug Abuse (NIDA) is Cocaine-Related Disorders with 17 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial